Search Results - Ansquer, J.C

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    P222 - Effet du fénofibrate sur la diméthylarginine symétrique et la diméthylarginine asymétrique chez des patients dyslipidémiques et diabétiques de type 2

    P222 - Effet du fénofibrate sur la diméthylarginine symétrique et la diméthylarginine asymétrique chez des patients dyslipidémiques et diabétiques de type 2 by Ansquer, J.C, Valensi, P, Dalton, R.N, Gottlieb, I, Le-Mouhaer, S, Conte, M

    Published in Diabetes & metabolism
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Micronised fenofibrate or gemfibrozil in patients with combined hyperlipidaemia: A double-blind randomised multicentre trial

    Micronised fenofibrate or gemfibrozil in patients with combined hyperlipidaemia: A double-blind randomised multicentre trial by Dzavik, V., Ansquer, J.C., Delaval, D.

    Published in Atherosclerosis
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Safety and efficacy of micronised fenofibrate 267 mg once daily for one year in type II dyslipidaemic patients at risk for coronary heart disease

    Safety and efficacy of micronised fenofibrate 267 mg once daily for one year in type II dyslipidaemic patients at risk for coronary heart disease by Krempf, M., Farnier, M., Rohmer, V., Borys, J.M., Vives, F., Mercier, F., Ansquer, J.C.

    Published in Atherosclerosis
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease. The Diabetes Atherosclerosis Intervention Study (DAIS)

    Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease. The Diabetes Atherosclerosis Intervention Study (DAIS) by Vakkilainen, J., Steiner, G., Ansquer, J.C.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    177 Lu-Dotatate améliore significativement la survie sans progression des patients atteints de tumeurs neuroendocrines métastatiques progressives de l’intestin moyen : résultats de l’essai de phase III NETTER-1

    177 Lu-Dotatate améliore significativement la survie sans progression des patients atteints de tumeurs neuroendocrines métastatiques progressives de l’intestin moyen : résultats de... by Ruszniewski, P, Courbon, F, Lebtahi, R, Giammarile, F, Lombard-Bohas, C, Ansquer, C, Matysiac, T, Guimbaud, R, Taieb, D, Seitz, J.F, Ducreux, M, Baudin, E, Yao, J.C, Hendifar, A, Krenning, E, Strosber, J

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Absence de valeur pronostique sur la survie de l’hypermétabolisme de la tumeur primitive dans les corticosurrénalomes malins

    Absence de valeur pronostique sur la survie de l’hypermétabolisme de la tumeur primitive dans les corticosurrénalomes malins by Tessonnier, L., Ansquer, C., Bournaud, C., Sebag, F., Mirallié, E., Lifante, J.C., Morange, I., Drui, D., Foucardère, C. De La, Taieb, D.

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: